Biovest to Seek Marketing Approval for BiovaxID® Personalized Lymphoma Cancer ... National Post While combination rituximab-chemotherapy regimens available today often induce tumor remissions in the early stages of treatment, these remissions seldom last; most patients relapse within years after discontinuing treatment. |
